BioWorld

Sep. 20, 2002

View Archived Issues

Biomira, Merck KGaA Miss Early Theratope Endpoints

Setting the bar high usually brings about one of two results: an exalting triumph or falling flat. (BioWorld Today) Read More

ISTA Secures $40M Financing As It Nears Vitrase NDA Filing

Read More

13 Is Lucky Number For Cohort In End-Stage Melanoma Treated With Counterintuitive Adoptive Transfer

Read More

Guilford Reports Positive Results From Follow-Up Of Gliadel Trial

Read More

Other News To Note

Read More

Endovasc Creates Subsidiaries For Two Late-Stage Products

Read More